Experimental multiplex biomarker analysis beats PSA for prostate cancer screening

March 2008
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p42
The article discusses research which examined an experimental multiplex biomarker analysis as a useful tool in detecting prostate cancer among patients with elevated prostate-specific antigens (PSA). It references a study published in a 2008 issue of "Cancer Research." The expression of 7 putative prostate cancer biomarkers in urine among patients presenting for biopsy or radical prostatectomy were measured by the researchers. They found that the multiplex model had a sensitivity of 65.9% and a specificity of 76.0%.


Related Articles

  • Surgery failed to reduce mortality from PSA-detected prostate cancer.  // Hem/Onc Today;9/10/2012, Vol. 13 Issue 17, p30 

    The article discusses a study led by Timothy J. Wilt of the Center for Chronic Disease Outcomes Research which reveals that radical prostatectomy failed to reduce mortality in patients diagnosed with early-stage prostate cancer after prostate-specific antigen (PSA) testing came into practice.

  • PSA and beyond: Biomarkers in prostate cancer. Huang, James G.; Campbell, Nicholas; Goldenberg, S. Larry // British Columbia Medical Journal;Sep2014, Vol. 56 Issue 7, p334 

    Prostate-specific antigen is one of the best-known bio-markers in medicine. Despite on-going debate on the utility of this proteolytic enzyme in population screening, PSA continues to play a role in the diagnosis and management of prostate cancer. In an attempt to move beyond problems related to...

  • JARGON BUSTER. MATILDA ELLIS // Daily Mail;11/19/2013, p39 

    MEDICAL terms decoded. This week: Biomarker IN MEDICINE a biomarker is a molecule, gene or characteristic that is linked to a particular disease or condition, or physical state.

  • PSA cutoffs no longer valid to determine biopsy. Overmyer, Mac // Urology Times;8/15/2005, Vol. 33 Issue 10, p34 

    Reports on a study questioning the value of established prostate specific antigen (PSA) cutoff points as a means of determining the need to conduct biopsies for prostate cancer. PSA biopsy thresholds used in prostate cancer detection; Argument that the lower the PSA, the better the results are...

  • Local therapy for prostate-specific antigen recurrence after definitive treatment. Meng, M V; Carroll, P R // Prostate Cancer & Prostatic Diseases;2001, Vol. 4 Issue 1, p20 

    Disease recurrence after local therapy for prostate cancer is increasingly common, most often with detectable or rising prostate-specific antigen (PSA) the earliest sign. Analysis of clinical and pathological factors can help determine which patients are at risk for treatment failure, while PSA...

  • Outcomes of extremely low risk prostate cancer following radical prostatectomy. Lee, E W; Laze, J; Lepor, H // Prostate Cancer & Prostatic Diseases;2011, Vol. 14 Issue 3, p266 

    The optimal management of men with very favorable clinicopathological factors who develop biochemical recurrence (BCR) after radical prostatectomy (RP) has not been previously reported. Both local and systemic recurrences are unlikely in this cohort. This study examines their management and...

  • pT3 PROSTATE CANCER. Akduman, Bulent; Crawford, David // Contemporary Urology;Apr2006, Vol. 18 Issue 4, p26 

    Offers criteria for use in determining which men with pathologic stage T3 disease and rising prostate-specific antigen (PSA) levels after radical prostatectomy (RP) can be offered adjuvant radiotherapy. Characteristics predictive of having an undetectable serum PSA level at 10 years in patients...

  • Diagnosticul ÇŽi tratamentul cancerului de prostatâ în stadiul localizat. Ambert, V.; Braticevici, B.; Damian, D.; Chira, I.; Jinga, V.; Iconaru, V.; Radu, T.; Constantin, T. // Romanian Journal of Urology;Sep2010, Vol. 9 Issue 3, p23 

    Introduction: The discovery of prostate specific antigen (PSA) and the use of serum markers represented a step forward in the diagnosis of prostate cancer (PC). Based on substantial clinical experience in diagnosis and treatment of PC (1442 PC cases admitted in our clinic during 2005-2009 and...

  • PSADT Predicts Post RP Death.  // Renal & Urology News;Apr2010, Vol. 9 Issue 4, p20 

    The article presents a study, conducted by Emmanuel S. Antonarakis of Johns Hopkins University in Baltimore, Maryland, which shows that prostate-specific antigen doubling time (PSADT) is the most significant predictor of 15-year overall survival in men experiencing biochemical recurrence after...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics